Edition:
United Kingdom

Pieris Pharmaceuticals Inc (PIRS.OQ)

PIRS.OQ on NASDAQ Stock Exchange Capital Market

7.39USD
2:52pm GMT
Change (% chg)

$0.47 (+6.79%)
Prev Close
$6.92
Open
$7.15
Day's High
$7.46
Day's Low
$7.15
Volume
40,154
Avg. Vol
93,220
52-wk High
$7.90
52-wk Low
$1.66

Select another date:

Wed, Dec 20 2017

BRIEF-Pieris Pharma Doses First Subjects In Phase I Study Of PRS-060

* PIERIS PHARMACEUTICALS-DOSED FIRST SUBJECTS IN PHASE I STUDY OF PRS-060, TRIGGERING $12.5 MILLION MILESTONE PAYMENT FROM ASTRAZENECA TO CO-SEC FILING Source text: (http://bit.ly/2oXTLTa) Further company coverage:

BRIEF-Pieris Pharma Received Clearance to Initiate Its First-In-Human Study In Australia For PRS-060/AZD1402

* PIERIS PHARMACEUTICALS - RECEIVED ETHICS AND REGULATORY CLEARANCE TO INITIATE ITS FIRST-IN-HUMAN STUDY IN AUSTRALIA FOR PRS-060/AZD1402

BRIEF-Pieris Pharmaceuticals appoints James Geraghty as chairman of board of directors

* Pieris Pharmaceuticals appoints James Geraghty as chairman of the board of directors

BRIEF-Pieris Pharmaceuticals reports Q3 loss per share $0.16

* Pieris Pharmaceuticals reports financial results for the third quarter ended september 30, 2017, and provides corporate update

BRIEF-Pieris Pharmaceuticals names Allan Reine CFO

* Pieris Pharmaceuticals appoints Allan Reine, M.D., as chief financial officer Source text for Eikon: Further company coverage:

BRIEF-Sichuan Kelun Pharmaceutical unit signs license agreement with Pieris Pharmaceuticals

* Says its Sichuan-based unit signs license agreement with Pieris Pharmaceuticals Inc, regarding a patent of tumour immunotherapy

BRIEF-Pieris Pharmaceuticals Q2 loss per share $0.23

* Pieris Pharmaceuticals reports financial results for the second quarter ended June 30, 2017 and provides corporate update

Select another date: